SCHEMBL9607191

SCHEMBL9607191

COc1cc(/C=C/C(=O)Nc2ccccc2C=O)ccc1O

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM1A O60341 7/20 0.78
▸ MMP9 P14780 4/20 0.67
▸ MMP1 P03956 3/20 0.67
▸ MMP2 P08253 3/20 0.67
▸ MEN1 O00255 3/20 0.58
▸ ALDH1A1 P00352 3/20 0.58
▸ TP53 P04637 3/20 0.58
▸ CYP3A4 P08684 3/20 0.58
▸ HPGD P15428 3/20 0.58
▸ KMT2A Q03164 3/20 0.58
▸ HIF1A Q16665 3/20 0.58
▸ CYP2C9 P11712 3/20 0.58
▸ HSD17B10 Q99714 3/20 0.58
▸ CYP1A2 P05177 2/20 0.58
▸ CYP2C19 P33261 2/20 0.58
▸ KDM4E B2RXH2 2/20 0.58
▸ PKM P14618 2/20 0.58
▸ ALOX12 P18054 2/20 0.58
▸ NFKB1 P19838 2/20 0.58
▸ MAPK1 P28482 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9607393 0.91 MMP1 (0.67) KDM1AMMP9MMP1MMP2MEN1
SCHEMBL13352244 0.91 MEN1 (0.71) KDM1AMMP9MMP1MMP2MEN1
SCHEMBL14290060 0.87 KDM1A (0.67) KDM1AMMP9MMP1MMP2MEN1
SCHEMBL20538352 0.87 KDM1A (0.72) KDM1AMMP9MMP1MMP2MEN1
SCHEMBL20538351 0.87 KDM1A (0.72) KDM1AMMP9MMP1MMP2MEN1
SCHEMBL13352028 0.86 KDM1A (0.82) KDM1AMMP9MMP1MMP2MEN1
SCHEMBL14319171 0.86 ALDH1A1 (0.71) KDM1AMMP9MMP1MMP2MEN1
SCHEMBL13352030 0.85 PKM (0.59) KDM1AMMP9MMP1MMP2MEN1
SCHEMBL13352031 0.85 MMP1 (0.75) KDM1AMMP9MMP1MMP2MEN1
SCHEMBL30568680 0.85 KDM1A (1.00) KDM1AMMP9MMP1MMP2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120315233-A1 ANTHRANILLIC ACID AMIDES AND DERIVATIVES THEREOF AS COSMETIC AND PHARMACEUTICAL ACTIVE COMPOUNDS SYMRISE AG (DE) 2012-12-13 — — US disclosed
WO-2012068612-A1 METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATION FIBROTECH THERAPEUTICS PTY LTD (AU) 2012-05-31 — — WO disclosed
WO-2008131481-A1 TREATMENT OF MESANGIOPROLIFERATIVE DISEASES FIBROTECH THERAPEUTICS PTY LTD (AU) 2008-11-06 — — WO disclosed
EP-1886662-A1 Anti-microbial compounds for treating bad breath Symrise GmbH & Co. KG (DE) 2008-02-13 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120315233-A1 ANTHRANILLIC ACID AMIDES AND DERIVATIVES THEREOF AS COSMETIC AND PHARMACEUTICAL ACTIVE COMPOUNDS CMA1, TPSAB1, HRH1 KDM1A 362/4885MMP9 606/4885MMP1 149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback